- Trade Name: Vonjo (CTI Biopharma)
- Indications:
Primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L
- Class: Janus kinase (JAK) inhibitor, Janus kinase-2 inhibitor, Kinase inhibitor
- Half-life: 28 hours
- FDA Approval Date: 02/28/2022
- Clinically important, potentially hazardous interactions with:
Clarithromycin, CYP3A4 inducers , CYP3A4 inhibitors, Rifampin - Pregnancy: No available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
